The Impact of Smoking and Obesity on Disability-Free Life Expectancy in Older Australians.


Journal

The journals of gerontology. Series A, Biological sciences and medical sciences
ISSN: 1758-535X
Titre abrégé: J Gerontol A Biol Sci Med Sci
Pays: United States
ID NLM: 9502837

Informations de publication

Date de publication:
14 06 2021
Historique:
received: 05 05 2020
pubmed: 30 11 2020
medline: 21 10 2021
entrez: 29 11 2020
Statut: ppublish

Résumé

Smoking and obesity are 2 modifiable risk factors for disability. We examine the impact of smoking and obesity on disability-free life expectancy (DFLE) at older ages, using 2 levels of disability. We used the DYNOPTA dataset, derived by harmonizing and pooling risk factors and disability outcomes from 5 Australian longitudinal aging studies. We defined mobility disability as inability to walk 1 km, and more severe (activities of daily living [ADL]) disability by the inability to dress or bathe. Mortality data for the analytic sample (N = 20 401; 81.2% women) were obtained from Government Records via data linkage. We estimated sex-specific total life expectancy, DFLE, and years spent with disability by Interpolated Markov Chain (IMaCh) software for each combination of smoking (never vs ever), obesity (body mass index ≥30 vs 18.5 to <30), and education (left school age 14 or younger vs age 15 or older). Compared to those without either risk factor, high educated nonobese smokers at age 65 lived shorter lives (men and women: 2.5 years) and fewer years free of mobility disability (men: 2.1 years; women: 2.0 years), with similar results for ADL disability. Obesity had the largest effect on mobility disability in women; high educated obese nonsmoking women lived 1.3 years less than nonsmoking, not obese women but had 5.1 years fewer free of mobility disability and 3.2 fewer free of ADL disability. Differences between risk factor groups were similar for the low educated. Our findings suggest eliminating obesity would lead to an absolute reduction of disability, particularly in women.

Sections du résumé

BACKGROUND
Smoking and obesity are 2 modifiable risk factors for disability. We examine the impact of smoking and obesity on disability-free life expectancy (DFLE) at older ages, using 2 levels of disability.
METHOD
We used the DYNOPTA dataset, derived by harmonizing and pooling risk factors and disability outcomes from 5 Australian longitudinal aging studies. We defined mobility disability as inability to walk 1 km, and more severe (activities of daily living [ADL]) disability by the inability to dress or bathe. Mortality data for the analytic sample (N = 20 401; 81.2% women) were obtained from Government Records via data linkage. We estimated sex-specific total life expectancy, DFLE, and years spent with disability by Interpolated Markov Chain (IMaCh) software for each combination of smoking (never vs ever), obesity (body mass index ≥30 vs 18.5 to <30), and education (left school age 14 or younger vs age 15 or older).
RESULTS
Compared to those without either risk factor, high educated nonobese smokers at age 65 lived shorter lives (men and women: 2.5 years) and fewer years free of mobility disability (men: 2.1 years; women: 2.0 years), with similar results for ADL disability. Obesity had the largest effect on mobility disability in women; high educated obese nonsmoking women lived 1.3 years less than nonsmoking, not obese women but had 5.1 years fewer free of mobility disability and 3.2 fewer free of ADL disability. Differences between risk factor groups were similar for the low educated.
CONCLUSIONS
Our findings suggest eliminating obesity would lead to an absolute reduction of disability, particularly in women.

Identifiants

pubmed: 33249489
pii: 6010465
doi: 10.1093/gerona/glaa290
pmc: PMC8202145
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1265-1272

Informations de copyright

© The Author(s) 2020. Published by Oxford University Press on behalf of The Gerontological Society of America.

Références

Int J Epidemiol. 2010 Feb;39(1):44-51
pubmed: 19151373
Lancet. 2015 Feb 7;385(9967):563-75
pubmed: 25468158
Lancet. 2015 Mar 14;385(9972):966-76
pubmed: 25784347
Am J Public Health. 2018 Dec;108(12):1652-1658
pubmed: 30359113
Am J Public Health. 2016 Jun;106(6):1079-85
pubmed: 26985619
Am J Public Health. 2006 Sep;96(9):1662-8
pubmed: 16873748
BMJ. 2019 Jun 20;365:l2219
pubmed: 31221636
NCHS Data Brief. 2013 Oct;(131):1-8
pubmed: 24152742
Popul Health Metr. 2013 Nov 19;11(1):21
pubmed: 24252500
Int J Epidemiol. 2016 Aug;45(4):1260-1270
pubmed: 27488415
Lancet. 2009 Mar 28;373(9669):1083-96
pubmed: 19299006
BMC Public Health. 2014 Jul 15;14:723
pubmed: 25026981
Soc Sci Med. 1999 Feb;48(4):445-69
pubmed: 10075171
Int J Surg Oncol (N Y). 2017 Aug;2(7):e17
pubmed: 29177227
Arch Intern Med. 2004 Jul 12;164(13):1413-20
pubmed: 15249350
PLoS One. 2016 Oct 19;11(10):e0165127
pubmed: 27760234
J Gerontol A Biol Sci Med Sci. 2019 Nov 13;74(12):1937-1943
pubmed: 31168573
Epidemiol Rev. 2007;29:29-48
pubmed: 17478442
Circ Cardiovasc Qual Outcomes. 2016 May;9(3):246-56
pubmed: 27166204
Arch Intern Med. 2007 Apr 23;167(8):750-1
pubmed: 17452535
Br Med Bull. 2013;105:185-99
pubmed: 23337796
BMC Public Health. 2009 Mar 25;9:88
pubmed: 19320986
N Engl J Med. 2009 Dec 3;361(23):2252-60
pubmed: 19955525
Lancet. 2012 Dec 15;380(9859):2144-62
pubmed: 23245606
Biol Sex Differ. 2018 Jun 27;9(1):28
pubmed: 29950175
Health Promot J Austr. 2017 Dec;28(3):255-259
pubmed: 28219013
BMC Med. 2014 Apr 07;12:59
pubmed: 24708705
Br J Gen Pract. 2007 Apr;57(537):319-23
pubmed: 17394736
Lancet Public Health. 2018 Sep;3(9):e447-e455
pubmed: 30174210
Prev Chronic Dis. 2012;9:E05
pubmed: 22172172
PLoS One. 2012;7(2):e31665
pubmed: 22355385
Int J Epidemiol. 2014 Dec;43(6):1874-83
pubmed: 25150976
Age Ageing. 2017 May 1;46(3):413-420
pubmed: 27932368
Obesity (Silver Spring). 2009 Apr;17(4):783-9
pubmed: 19165165
N Engl J Med. 2010 Dec 2;363(23):2211-9
pubmed: 21121834
Int J Obes (Lond). 2008 Feb;32(2):211-22
pubmed: 17848940
Aust N Z J Public Health. 2019 Apr;43(2):163-170
pubmed: 30830711
Lancet. 2018 Nov 10;392(10159):1859-1922
pubmed: 30415748
Health Aff (Millwood). 2017 Jul 19;:
pubmed: 28724530
Cold Spring Harb Perspect Med. 2015 Nov 02;5(11):
pubmed: 26525456
Lancet. 2016 Feb 20;387(10020):779-86
pubmed: 26680218
J Gerontol A Biol Sci Med Sci. 2020 Apr 17;75(5):952-960
pubmed: 31750880
J Gerontol A Biol Sci Med Sci. 2019 Nov 13;74(12):1944-1951
pubmed: 31120111
Vasc Health Risk Manag. 2019 May 01;15:89-100
pubmed: 31118651
Value Health. 2018 Mar;21(3):364-371
pubmed: 29566844
Obesity (Silver Spring). 2011 Jul;19(7):1451-9
pubmed: 21415846

Auteurs

Andrew Kingston (A)

Population Health Sciences Institute, Newcastle University, Newcastle upon Tyne, UK.

Julie Byles (J)

Research Centre for Generational Health and Ageing, University of Newcastle, New South Wales, Australia.
Hunter Medical Research Institute, Newcastle, New South Wales, Australia.

Kim Kiely (K)

School of Psychology, University of New South Wales, Sydney, Australia.
Neuroscience Research Australia (NeuRA), Sydney, New South Wales, Australia.

Kaarin J Anstey (KJ)

School of Psychology, University of New South Wales, Sydney, Australia.
Neuroscience Research Australia (NeuRA), Sydney, New South Wales, Australia.

Carol Jagger (C)

Population Health Sciences Institute, Newcastle University, Newcastle upon Tyne, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH